

In Vitro Antimicrobial Activity of Medicinal Plants against Oral *Candida albicans* Isolates

Candice Van Wyk¹ • Francien Susanna Botha¹ • Vanessa Steenkamp^{2*}

¹ Department of Community Dentistry, School of Dentistry, University of Pretoria, PO Box 1266, Pretoria, 0001, South Africa

² Department of Pharmacology, School of Medicine, University of Pretoria, PO Box 1266, Pretoria, 0001, South Africa

Corresponding author: * vanessa.steenkamp@up.ac.za

ABSTRACT

In most countries of subtropical Africa, bacterial and fungal infections represent an increasing problem, particularly with patients suffering from severe immune deficiencies. *Candida* species are responsible for a wide range of systemic as well as superficial opportunistic infections. *Candida albicans* is a normal commensal, isolated intraorally in 17 to 75% of healthy individuals and all debilitated people. Eradication of candidiasis is complicated by the emergence of *Candida* strains that are resistant to the currently used antifungal agents. Furthermore, these antifungal agents are limited in number, are costly and in addition may be toxic. Plants as remedies are used by ~80% of the population in developing countries and their use is gaining popularity in developed countries. Although, many plants have already been investigated for their antifungal activity against *C. albicans* the search is still on to find a long-term prevention or cure for oral candidiasis. It is essential that such a product will prevent a recurrence of the condition, be inexpensive and prevent the development of antifungal resistance.

Keywords: antifungal, candidiasis, herbal remedies, inhibition

CONTENTS

| | |
|--|----|
| INTRODUCTION..... | 26 |
| CANDIDA ALBICANS IN THE ORAL CAVITY..... | 26 |
| TREATMENT OF ORAL CANDIDIASIS..... | 27 |
| Conventional therapy..... | 27 |
| Herbal remedies..... | 27 |
| REFERENCES..... | 29 |

INTRODUCTION

In most countries of subtropical Africa, bacterial and fungal infections represent an increasing problem, particularly with patients suffering from severe immune deficiencies, such as Acquired Immunodeficiency Syndrome (AIDS) (Atindehou *et al.* 2002). *Candida* species are responsible for a wide range of systemic as well as superficial opportunistic infections (candidiasis) occurring most frequently in vaginal or oral mucosa (Cannon *et al.* 1995; Williams *et al.* 1997). *Candida* species are normal oral commensals (Samaranayake 1990), and are isolated intraorally in 17 to 75% of healthy individuals (Arendorf and Walker 1980; Bastiaan and Reade 1982; Rindum *et al.* 1994) and all debilitated people.

The adhesion of microbes to the host's mucosal surfaces is a major determinant of successful microbial colonization and subsequent infection, and its critical role in the pathogenesis of many fungal infections is well recognized (King *et al.* 1980; Shibl 1985; Fukazawa and Kagaya 1997). Various *in vitro* studies (Samaranayake and MacFarlane 1981a, 1982) and animal studies (McCourtie and Douglas 1984; Calderone *et al.* 1985) provide evidence for a relationship between the proclivity of *Candida* species to adhere to mucosal surfaces and their presence in infections. Therefore, candidal adherence to human buccal epithelial cells (HBEC) is considered the critical initial step in the pathogenesis of oral candidiasis, which may eventually lead to a systemic infection, especially in immuno-compromised

people (Schafer-Korting *et al.* 1996).

Plants as remedies are used by ~80% of the population in developing countries and their use is gaining popularity in developed countries (Ernst 2005). Medicinal plants have attracted considerable research attention as new sources of antimicrobial agents. A wide variety of plant extracts have antimicrobial effects and anti-inflammatory properties, and several herbal extracts have been added to some cosmetics and health-care preparations (Taweechaisupapong *et al.* 2005).

This short review describes the occurrence of *C. albicans* in the oral cavity as well as the treatment of candidiasis with conventional medication and herbal remedies.

CANDIDA ALBICANS IN THE ORAL CAVITY

C. albicans is a fungus that can grow in a number of morphological forms, ranging from yeast to hyphae (Cannon *et al.* 1995). Pseudohyphal forms are also seen, and this morphology can be assumed by several other *Candida* species (Odds 1988). Sherwood *et al.* (1992) demonstrated that hyphae are capable of contact-sensing or thigmotropism. *C. albicans* hyphae incubated on perforated filters over agar plates have been shown to grow through the pores and along grooves, possibly facilitating the penetration of some tissues. Certain *C. albicans* strains exhibit high-frequency switching of colony morphology when nutritionally stressed and this can be accompanied by chromosomal translocation allowing the asexual *C. albicans* to adapt to environmental

change (Soll 1992). Evidence has confirmed that *C. albicans* cell surface modulation occurs *in vivo* (De Benardis *et al.* 1994). These surface changes may enable a commensal yeast strain to escape immune surveillance (Diamond 1993) or adhere to different host receptors, thereby promoting candidiasis (Cannon *et al.* 1995). Changes in surface protein glycosylation may expose hydrophobic protein structures at the cell surface (Hazen and Glee 1994), in turn affecting adherence properties. Yeast cell surface changes may be brought about by *Candida*-host interactions as adherence to human buccal epithelial cells induces the synthesis of new proteins in *C. albicans* and the expression of signal proteins (Bailey *et al.* 1995). An understanding of adherence mechanisms, the signals they generate and the processes that they induce, may therefore lead to specific preventive treatments for individuals predisposed to candidiasis (Cannon *et al.* 1995).

A diverse array of host factors has been implicated in the pathogenesis of oral candidiasis (Samaranayake 1990). The local factors are mucosal barrier, saliva, phagocytes, and the morphogenesis of *C. albicans*. The systemic factors are: immuno-compromised individuals (patients with diseases such as diabetes mellitus, leukemia, AIDS, and cancer) and altered nutritional factors (such as iron and vitamin deficiency). Iatrogenic factors include antibiotic therapy, corticosteroid therapy, cytotoxic and radiotherapy (irradiation) and cigarette/tobacco smoking (Samaranayake 1990). These local and systemic factors act in concert and the eventual outcome of these disease processes are frequently related to the superimposition of the local factors upon systemic factors or *vice versa*.

TREATMENT OF ORAL CANDIDIASIS

Conventional therapy

Patients with oral candidiasis have painful mouths and experience difficulty with eating and swallowing. These patients are treated with the membrane-active polyenes nystatin and amphotericin B, usually administered as a suspension or lozenges, while the ergosterol biosynthesis inhibitors (imidazoles and triazoles) are administered as tablets (miconazole, ketoconazole, and fluconazole), as a gel (miconazole), or as troches (clotrimazole) (Budtz-Jørgensen 1990b; Martin 1990; Cannon *et al.* 1995). Exposure of HBEC to amphotericin B, nystatin (Macura 1988; Abu-Elteen *et al.* 1989) and ketoconazole (King *et al.* 1980; Sobel and Obedeau 1983) have been shown to inhibit germination of *Candida* species and reduce attachment to human epithelial cells leading to a reduction in oral candidiasis. However, eradication of candidiasis is complicated by the emergence of strains of *Candida* that are resistant to the currently used antifungal agents (Perea *et al.* 2001; Khan *et al.* 2003). The currently used antifungal agents are limited in number, are costly and in addition may be toxic (Salie *et al.* 1996; Mehta *et al.* 2002; Ship *et al.* 2007). Furthermore, the social stigma associated with the HIV disease in many developing regions in Africa and Asia appears to modify the therapeutic strategies and management of fungal infections (Samaranayake *et al.* 2002). Relapse of *Candida* infections is also very common (Debruyne 1997) and this increases the burden of managing this opportunistic infection. These factors prompt the need for development of new antifungal agents in order to widen the spectrum of activities against *Candida* species and combat strains expressing resistance to the available antifungals.

Herbal remedies

Natural products have been used worldwide for medicinal purposes for thousands of years (Patel and Coogan 2008). In many developing countries, a large number of people depend on medicinal plants as their primary source of medication. Up to a quarter of all prescriptions in industrialised countries contain one or more components derived from

plants (Farnsworth 1990). Medicinal plants are frequently employed in oral-health; the twigs of plants have been used as "toothbrushes" whereas leaf tinctures are used as mouthwashes (Lewis 1980).

Streblus asper Lour (Moraceae; toothbrush tree) is used for the treatment of a variety of oral complaints; the bark for relief of fever, dysentery, toothache and gingivitis (Gaitonde *et al.* 1964) and the twigs as a "toothbrush" for strengthening teeth and gums (Lewis 1980). Antibacterial activity against endodontic and periodontal pathogens has been demonstrated for the ethanolic leaf extract of *Streblus asper* (Taweekhaisupapong *et al.* 2000a, 2002a). Moreover, mouthwashes containing the ethanolic extract have been shown to improve gingival health (Taweekhaisupapong *et al.* 2002b). Regarding the *in vitro* adhesion of *C. albicans* to HBEC, Taweekhaisupapong *et al.* (2005) found that *Streblus asper* leaf extract significantly ($p < 0.05$) reduces adherence of *C. albicans* to HBEC after one hour pre-treatment exposure to the extract. The mechanism responsible for inhibition of adherence by *S. asper* extracts remains undetermined, but it could include alterations to cell surface features that in turn masts the adhesions present on the yeast or on the receptors present on the buccal cells. Other possibilities are that *S. asper* extract interferes with the synthesis of adhesins that are involved in the adhesion process, or that it causes a mechanical distortion of the adhesins already present in the outer envelopes, thereby blocking adherence (Taweekhaisupapong *et al.* 2005). Exposure of HBEC to garlic extract (Ghannoum 1990) and date extract (Abu-Elteen 2000) have shown inhibition of germination of *Candida* species and reduced attachment to human epithelial cells, leading to a reduction in oral candidiasis. The inhibition of germ tube formation is important since it is well known that germ tube and mycelial forms of *C. albicans* adhere more efficiently to host cells than do yeast cells (Kimura and Pearsall 1980; Sobel *et al.* 1981; Hostetter 1994; Pendrak and Klotz 1995).

Decoctions of the leaves of *Dodonaea viscosa* var. *angustifolia* (hopbush) have been used since the 1700's and are still used today for the treatment of oral infections (Van Wyk *et al.* 2002; Patel and Coogan 2008). This plant has analgesic activity (Amabeoku *et al.* 2001), antiviral activity (against both Human immunodeficiency virus (HIV) 1 and 2) and is non-toxic (Asres *et al.* 2001). These properties suggest that the extract has the potential to be used as an effective mouthrinse for the prevention of recurrent oral candidiasis by reducing the number of *Candida* species in the mouth to an acceptable level (Patel and Coogan 2008). Furthermore, the analgesic activity contributes to reducing the pain in the mouth, a symptom of patients with oral candidiasis. Lawsone methyl ether, isolated from *Rhinacanthus nasutus* (dainty spurs) leaves possesses potent antifungal activity, making it a cost-effective mouthrinse (Blignaut *et al.* 2006).

In a study to identify a traditional remedy to treat oral candidiasis, Motsei *et al.* (2003) reported that *Allium sativum* (garlic), *Glycyrrhiza glabra* (liquorice), *Polygala myrtifolia* (August/September bush) and *Tulbaghia violacea* (wild garlic) inhibited growth of the standard strain (ATCC10231) and two clinical isolates of *C. albicans* (isolated from a 5-month-old baby and an adult). *Glycyrrhiza glabra* and *Polygala senega* (Seneca snakeroot) are also extensively used in Europe as treatment for oral candidiasis. Both plants contain saponins, compounds known to possess antifungal activity (Bruneton 1995). Thin layer chromatography (TLC)-bioautography has indicated several active compounds in *Allium sativum* and *Tulbaghia violacea* bulb extracts, one being allicin. Allicin is the active compound in garlic containing antimicrobial and antifungal properties against most Gram-positive and Gram-negative bacteria, as well as *C. albicans* (Wagner and Bladt 1996; Ankri and Mirelman 1999). Allicin's main antimicrobial effect is ascribed to its chemical reaction with the thiol groups of various enzymes (Ankri and Mirelman 1999). Furthermore, Ghannoum (1988) reported that the inhibitory effect of

Table 1 Summary of the plants identified in literature and mentioned in the text with antimicrobial activity against *C. albicans*.

| Plant name (Latin binomial, common name) | Family | Active Constituent(s) | Activity Noted | Mechanism of Action | MIC Concentration mg/ml | Clinical Trial | References |
|--|---------------|--|----------------------------------|--|--|----------------|--|
| <i>Acacia nilotica</i> Black thorn tree | Fabaceae | Tannins | Activity noted | Antimicrobial action | - | Yes | Runyoro <i>et al.</i> 2006 |
| <i>Allium sativum</i> Garlic | Alliaceae | Thiol | Weak activity | Oxidation of thiol thus inactivation of enzymes and microbial growth | H ₂ O 6.25 | Yes | Ghannoum, 1988; Motsei <i>et al.</i> 2003 |
| <i>Balanites aegyptiaca</i> Simple thorned torch tree, Jericho balsam | Balanitaceae | Saponins | Weak activity | Antimicrobial action of saponins is well known | - | Yes | Runyoro <i>et al.</i> 2006 |
| <i>Combretum molle</i> Velvet bush willow | Combretaceae | Tannins | Weak activity - High activity | - | H ₂ O 6.50 M1.00 | Yes | Runyoro <i>et al.</i> 2006 |
| <i>Curtisia dentata</i> Cape lancewood | Cornaceae | Flavonoids, phenolic compounds, terpenoids | High activity | - | D 0.15 A 0.12 H 0.60 | Yes | Shai 2007 |
| <i>Cussonia zuluensis</i> Cabbage tree | Araliaceae | Saponins, tannins | High activity | - | D 1.88 A 1.25 | Yes | Shai 2007 |
| <i>Dichrostachys cinerea</i> Chinese lantern tree, Kalahari Christmast tree, sicklebush | Fabaceae | Triterpenes, sterols, tannins | Activity noted | Not known, may be due to combination of active ingredients | - | No | Runyoro <i>et al.</i> 2006 |
| <i>Dioscorea minutiflora</i> Ivory Coast wild yam | Dioscoreaceae | Saponins, diosgenin, heterosides | High activity | - | 100 µg/ml on plate for TLC | Yes | Quigley 1978; Atindehou <i>et al.</i> 2002 |
| <i>Dodonaea viscosa</i> var. <i>Angustifolia</i> Hopbush | Sapindaceae | Diterpenoids, dodonic acid, hautriwaic acid | Weak to high activity | Details of its exact action are not available | H ₂ O >25 EtOH 2.09 EtOAc 1.04 H >8.35 | Yes | Van Wyk <i>et al.</i> 2002; Motsei <i>et al.</i> 2003 |
| <i>Eriocephalus africanus</i> Cape of Good Hope shrub | Asteraceae | Dehydrofalcarin, sesquiterpenoid lactones, ivangustine | - | - | - | No | Van Wk <i>et al.</i> 2002 |
| <i>Glycyrrhiza glabra</i> Liquorice | Fabaceae | Saponins, chalcones, flavonoids, isoflavonoids | High activity | Not known, may be due to combination of active ingredients | H ₂ O 12.5 EtOH 2.09 EtOAc 2.09 H >8.35 | Yes | Bruneton 1995; Motsei <i>et al.</i> 2003 |
| <i>Helichrysum crispum</i> Hottentots bedding | Asteraceae | Flavonoids, sesquiterpenoids, acylated phloroglucinols | - | - | - | No | Van Wyk <i>et al.</i> 2002 |
| <i>Kigelia africana</i> Sausage tree | Bignoniaceae | Naphthoquinone lapachol, Dihydroisocoumarin kigelin | High activity | Beneficial effect may be due to the dihydroisocoumarins and their glycosides | H 0.45 D 0.23 A 0.23 | Yes | Shai, 2007 |
| <i>Ozoroa insignis</i> Tropical resin tree | Anacardiaceae | Not known | Activity noted | Not known | - | No | Runyoro <i>et al.</i> 2006 |
| <i>Polygala myrtifolia</i> August/September bush | Polygalaceae | Saponins | Weak activity | Saponins are well documented for their antimicrobial activity | H ₂ O 6.25 EtOH 8.35 EtOAc >8.35 H >8.35 | Yes | Motsei <i>et al.</i> 2003 |
| <i>Polygala myrtifolia</i> August/September bush | Polygalaceae | Saponins | Weak activity | Saponins are well documented for their antimicrobial activity | H ₂ O 6.25 EtOH 8.35 EtOAc >8.35 H >8.35 | Yes | Motsei <i>et al.</i> 2003 |
| <i>Salvadora persica</i> Toothbrush tree | Salvadoraceae | - | Activity noted | - | - | Yes | Runyoro <i>et al.</i> 2006 |
| <i>Sclerocarya birrea</i> Marula | Anacardiaceae | Procyanidins, gallotannins, flavonoids, catechin | Activity noted | Not known, may be due to combination of active ingredients | - | No | Van Wyk <i>et al.</i> 2002; Runyoro <i>et al.</i> 2006 |
| <i>Securidaca longepedunculata</i> Violet tree | Polygalaceae | Methyl salicylate, saponins | Activity noted | Presence of salicylate (winter green oil) may explain recorded uses | - | Yes | Van Wyk <i>et al.</i> 2002; Runyoro <i>et al.</i> 2006 |
| <i>Streblus asper</i> Toothbrush tree | Moraceae | - | Weak activity | Reduce germ tube formation | EtOH 15.6 | Yes | Taweechai-supapong <i>et al.</i> 2005 |
| <i>Terminalia phanerophlebia</i> Lebombo cluster-leaf | Combretaceae | Tannins, saponins | High activity | Triterpenoids and saponins are well known for their antimicrobial activity | H 0.30 D 0.30 A 0.15 | Yes | Shai 2007 |
| <i>Terminalia sambesiaca</i> | Combretaceae | Tannins, saponins | High activity | Triterpenoids and saponins are well known for their antimicrobial activity | H 0.23 D 0.23 A 0.12 | Yes | Shai 2007 |
| <i>Trichilia emetica</i> Natal mahogany | Meliaceae | Limonoids, tannins | Weak activity | Exact pharmacological effects appear to be unknown | H ₂ O >25 EtOH >8.35 EtOAc >8.35 H >8.35 | Yes | Shai 2007 |

Table 1 (Cont.)

| Plant name (Latin binomial, common name) | Family | Active Constituent(s) | Activity Noted | Mechanism of Action | MIC Concentration mg/ml | Clinical Trial | References |
|--|--|---|----------------|--|--|----------------|--|
| <i>Tulbaghia violacea</i> Wild garlic | Amaryllidaceae | Allicin | Weak activity | Oxidation of thiol thus inactivation of enzymes and microbial growth | H ₂ O 12.5 ETOH 2.09 ETOAc 2.09 H 8.35 | Yes | Wagner and Bladt 1996; Ankri and Mirrelman 1999; Motsei <i>et al.</i> 2003 |
| <i>Zanha africana</i> Velvet-fruited zanha | Sapindaceae | Not known | Activity noted | - | - | No | Runyoro <i>et al.</i> 2006 |
| <i>Ziziphus mucronata</i> Buffalo thorn | Rhamnaceae | Alkaloids (peptide alkaloids), mucronine D | Activity noted | Not known | - | No | Van Wyk <i>et al.</i> 2002; Runyoro <i>et al.</i> 2006 |
| <i>Verpris reflexa</i> bushveld white-ironwood | Rutaceae | Tannins, quinolone alkaloids (veprisinium salt) | High activity | Not known, may be due to combi-nation of ac-tive ingredients | H 1.25 D 1.25 A 1.25 | Yes | Shai 2007 |
| ETOH - ethanol ETOAc - ethyl acetate | H ₂ O - water H - hexane | | | D - dichloromethane A - acetibe | M - Methanol - - no data | | |

garlic against yeast is attributed to the oxidation of essential protein thiol, causing inactivation of enzymes and subsequent microbial growth inhibition.

Plants from Tanzania with antifungal activity against *C. albicans* and used to treat oral candidiasis include: dried fruits of *Acacia nilotica* (black thorn tree); saponin fraction from the mesocarp of *Balanites aegyptiaca* (simple thorned torch tree, Jericho balsam); methanolic extract of the leaf of *Cajanus cajan* (pigeon pea); fruits, roots, latex and leaves of *Carica papaya* (papaya); methanol extract of the dried bark of *Combretum molle* (velvet bush willow); dried stem of *Dichrostachys cinerea* (Chinese lantern tree, Kalahari Christmas tree (South Africa), sicklebush); methanol extract of dried root bark of *Harrisonia abyssinica*; dried stem bark of *Ozoroa insignis* (tropical resin tree); roots of *Salvadora persica* (toothbrush tree); ethanolic extract of dried stem-bark of *Sclerocarya birrea* (marula); aqueous, dichloromethane and ethanolic extracts of *Securidaca longepedunculata* (violet tree); aqueous and methanol extracts of the stem-bark of *Ziziphus mucronata* (buffalo thorn) and stem-bark of *Zanha africana* (velvet-fruited zanha). Some of these plants also inhibited *Cryptococcus neoformans* growth, which is an important pathogenic fungi in HIV/AIDS (Runyoro *et al.* 2006).

Lipophilic extracts of the leaves of *Eriocephalus africanus* L. (Cape of Good Hope shrub), stems of *Helichrysum crispum* (L.) D. Don. (Hottentots bedding) and leaves of *Felicia erigeroides* DC. (Felicia) possesses *in vitro* antimicrobial activity, amongst others against the fungus *C. albicans* (Salie *et al.* 1996). The herbal remedies: *Curtisia dentata* (Cape lancewood); *Trichilia emetica* (Natal mahogany); *Kigelia africana* (sausage tree); *Terminalia sambesiaca*; *Vepris reflexa* (bushveld white-ironwood); *Terminalia phanerophlebia* (Lebombo cluster-leaf) and *Cussonia zuluensis* (cabbage tree) have shown promising inhibitory activity against *C. albicans* with minimal inhibitory concentration (MIC) values of the crude extracts between 0.08-1.0 mg/ml (Shai 2007). One-hundred and fifteen plants used as traditional medicine in the Ivory Coast were evaluated by Atindehou *et al.* (2002) for antibacterial and antifungal activity, which included *C. albicans* and *Cladosporium cucumerinum*. *Dioscorea minutiflora* (Ivory Coast wild yam), and *Erythrina vogelii* ('Ouossoupalie' à Fleurs rouges (French)/red flower tree), contained the best antifungal activity. Interestingly, young tubers of *D. minutiflora* displayed strong antifungal activity whereas older tubers did not show any antifungal properties. This could be due to the presence of diosgenin heterosides in the young tubers and their absence in the old tubers of *Dioscorea* species, previously reported in West Africa (Quigley 1978). The plants containing activity against *C. albicans* have been summarised in Table 1.

In conclusion, although many plants have been investi-

gated to determine their antifungal activity against *C. albicans*, the search is still on to find a long-term prevention or cure for oral candidiasis. This product should prevent recurrence of the condition, be inexpensive and prevent the development of antifungal resistance. The plant compound/s isolated thus far and presented in the text and Table should be further researched as these could play a role in future drug development.

REFERENCES

- Abu-Elteen KH, Ghannoum MA, Stretton RJ (1989) Effects of sub-inhibitory concentrations of antifungal agents on adherence of *Candida* spp. to buccal epithelial cells *in vitro*. *Mycoses* **32**, 551-562
- Abu-Elteen KH (2000) Effects of date extract on adhesion of *Candida* species to human buccal epithelial cells *in vitro*. *Journal of Oral Pathology and Medicine* **29**, 200-205
- Amabeoku GJ, Eagles P, Scott G, Mayeng I, Springfield E (2001) Analgesic and antipyretic effects of *Dodonaea angustifolia* and *Salvia africana-lutea*. *Journal of Ethnopharmacology* **75**, 117-124
- Ankri S, Mirelman D (1999) Antimicrobial properties of allicin from garlic. *Microbes and Infection* **2**, 125-129
- Arendorf TM, Walker DM (1980) The prevalence and intra-oral distribution of *Candida albicans* in man. *Archives of Oral Biology* **25**, 1-10
- Asres K, Bucar F, Kartnig T, Witvrouw M, Pannecouque C, De Clercq E (2001) Antiviral activity against human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) of ethnobotanically selected Ethiopian medicinal plants. *Phytotherapy Research* **15**, 62-69
- Atindehou KK, Kone M, Terreaux C, Traore D, Hostettmann K, Dosso M (2002) Evaluation of the antimicrobial potential of medicinal plants from the Ivory Coast. *Phytotherapy Research* **16**, 497-502
- Bailey A, Wadsworth E, Calderone R (1995) Adherence of *Candida albicans* to human buccal epithelial cells: host-induced protein synthesis and signaling events. *Infection and Immunity* **63**, 569-572
- Bastiaan RJ, Reade PC (1982) The prevalence of *Candida albicans* in the mouths of tobacco smokers with and without oral mucous membrane keratoses. *Oral Surgery, Oral Medicine, And Oral Pathology* **53**, 148-151
- Blignaut E, Patton LL, Nittayananta W, Ramirez-Amador V, Ranganathan K, Chattopadhyay A (2006) (A3) HIV phenotypes, oral lesions, and management of HIV-related disease. *Advances in Dental Research* **19** (1), 122-129
- Bruneton J (1995) *Pharmacognosy, Phytochemistry, Medicinal Plants*, Intercept Ltd., Andover, 928 pp
- Budtz-Jørgensen E (1990b) Etiology, pathogenesis, therapy and prophylaxis of oral yeast infections. *Acta Odontologica Scandinavica* **48**, 61-69
- Calderone RA, Chilar RL, Lee DD, Hoberg K, Scheld WM (1985) Yeast adhesion in the pathogenesis of endocarditis due to *Candida albicans*: studies with adherence-negative mutants. *The Journal of Infectious Diseases* **152**, 710-715
- Cannon RD, Holmes AR, Mason AB, Monk BC (1995) Oral *Candida*: clearance, colonization, or candidiasis? *Journal of Dental Research* **74** (5), 1152-1161
- Debruyne D (1997) Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. *Clinical Pharmacokinetics* **33**, 52-77
- De Benardis F, Molinari A, Boccanera M, Stingaro A, Robert R, Senet J-M (1994) Modulation of cell surface-associated mannoprotein antigen expression in experimental candidal vaginitis. *Infection and Immunity* **62**, 509-519
- Diamond RD (1993) Interactions of phagocytic cells with *Candida* and other

- opportunistic fungi. *Archives of Medical Research* **24**, 361-369
- Ernst E** (2005) The efficacy of herbal medicine – an overview. *Fundamental and Clinical Pharmacology* **19**, 405-409
- Farnsworth NR** (1990) Bioactive compounds from plants. In: Ciba Foundation Symposium 154, John Wiley and Sons, UK, p 2
- Fukazawa Y, Kagaya K** (1997) Molecular bases of adhesion of *Candida albicans*. *Journal of Medical and Veterinary Mycology* **35**, 87-99
- Gaionde B, Vaz A, Patel J** (1964) Chemical and pharmacological study of root bark of *Streblus asper*. *Indian Journal of Medical Sciences* **18**, 191-199
- Ghannoum MA** (1988) Studies on the anticandidal mode of action of *Allium sativum* (garlic). *Journal of General Microbiology* **134**, 2917-2924
- Ghannoum MA** (1990) Inhibition of *Candida* adhesion to buccal epithelial cells by an aqueous extract of *Allium sativum* (garlic). *The Journal of Applied Bacteriology* **68**, 163-169
- Hazen KC, Glee PM** (1994) Hydrophobic cell wall protein glycosylation by the pathogenic fungus *Candida albicans*. *Canadian Journal of Microbiology* **40**, 266-272
- Hosletter MK** (1994) Adhesins and ligands involved in the interaction of *Candida* spp. with epithelial and endothelial surfaces. *Clinical Microbiology Reviews* **7**, 29-42
- Khan ZU, Chandy R, Metwali KE** (2003) *Candida albicans* strain carriage in patients and nursing staff of an intensive care unit: a study of morphotypes and resistotypes. *Mycoses* **46**, 476-486
- Kimura LH, Pearsall NN** (1980) Relationship between germination of *Candida albicans* and increased adherence to human buccal epithelial cells. *Infection and Immunity* **28**, 464-468
- King RD, Lee JC, Morris AL** (1980) Adherence of *Candida albicans* and other *Candida* species to mucosal epithelial cells. *Infection and Immunity* **27**, 667-674
- Lewis W** (1980) Plants used as chewing sticks. *The Journal of Preventive Dentistry* **6**, 71-73
- Macura AB** (1988) The influence of some antifungal drugs on *in vitro* adherence of *Candida albicans* to human buccal epithelial cells. *Mycoses* **31**, 371-376
- Martin MV** (1990) Antifungal agents. In: Samaranayake LP, MacFarlane TW (Eds) *Oral Candidiasis*, Butterworth, London, pp 238-251
- McCourtie J, Douglas LJ** (1984) Relationship between cell surface composition, adherence and virulence of *Candida albicans*. *Infection and Immunity* **45**, 6-12
- Mehta DK, Martin J, Jordan B, MacFarlane CR, Hashimi FT, Kouimtzis M, Ryan RSM, Shing T, Wagle SMS, Gallagher GP** (2002) *British National Formulary*, London, Pharmaceutical Press, pp 294-298
- Motsei ML, Lindsey KL, van Staden J, Jäger AK** (2003) Screening of traditionally used South African plants for antifungal activity against *Candida albicans*. *Journal of Ethnopharmacology* **86**, 235-241
- Odds FC** (1988) *Candida and Candidosis: A Review and Bibliography* (2nd Ed), Baillière Tindall, London, 384 pp
- Patel M, Coogan MM** (2008) Antifungal activity of the plant *Dodonaea viscosa* var. *angustifolia* on *Candida albicans* from HIV-infected patients. *Journal of Ethnopharmacology* **118**, 173-176
- Pendrak ML, Klotz SA** (1995) Adherence of *Candida albicans* to host cells. *FEMS Microbiology Letters* **129**, 103-113
- Perea S, López-Ribot JL, Kirkpatrick WR, McAtee RK, Santillán RA, Martínez M, Calabrese D, Sanglard D, Patterson TF** (2001) Prevalence of molecular mechanisms of resistance to azole antifungal agents in *Candida albicans* strains, displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. *Antimicrobiology Agents and Chemotherapy* **45**, 2676-2684
- Quigley FR** (1978) Diosgenin in West African *Dioscorea* plants. *Planta Medica* **33**, 414-415
- Rindum JL, Stenderup A, Holmstrup P** (1994) Identification of *Candida albicans* types related to healthy and pathological oral mucosa. *Journal of Oral Pathology and Medicine* **23**, 406-412
- Runyoro DKB, Ngassapa OD, Matee MIN, Joseph CC, Moshi MJ** (2006) Medicinal plants used by Tanzanian traditional healers in the management of *Candida* infections. *Journal of Ethnopharmacology* **106**, 158-165
- Salie F, Eagles PFK, Leng HMJ** (1996) Preliminary antimicrobial screening of four South African Asteraceae species. *Journal of Ethnopharmacology* **52**, 27-33
- Samaranayake LP** (1990) Host factors and oral candidosis. In: Samaranayake LP, MacFarlane TW (Eds) *Oral Candidosis*, Wright, London, pp 66-103
- Samaranayake LP, MacFarlane TW** (1981a) The adhesion of the yeast *Candida albicans* to epithelial cells of human origin *in vitro*. *Archives of Oral Biology* **26**, 815-820
- Samaranayake LP, MacFarlane TW** (1982) Factors affecting the *in vitro* adherence of the fungal oral pathogen *Candida albicans* to epithelial cells of human origin. *Archives of Oral Biology* **27**, 869-873
- Samaranayake LP, Fidel PL, Naglik JR, Sweet SP, Teanpaisan R, Coogan MM, Blignaut E, Wanzala P** (2002) Fungal infections associated with HIV infection. *Oral Diseases* **8** (2), 151-160
- Schafer-Korting M, Blechschmidt J, Korting HC** (1996) Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk. *Mycoses* **39**, 329-339
- Shai LJ** (2007) Characterization of compounds from *Curtisia dentata* (Cornaceae) active against *Candida albicans*. PhD thesis, Department of Paraclinical Sciences, University of Pretoria, Pretoria, South Africa, pp 13-14, 26, 29, 41
- Sherwood J, Gow NAR, Gooday GW, Gregory DW, Marshall D** (1992) Contact sensing in *Candida albicans*: a possible aid to epithelial penetration. *Journal of Medical and Veterinary Mycology* **30**, 461-469
- Shibl AM** (1985) Effect of antibiotics on adherence of micro-organisms to epithelial cell surfaces. *Reviews of Infectious Diseases* **7**, 51-65
- Ship JA, Vissink A, Challacombe SJ** (2007) Use of prophylactic antifungals in the immuno-compromised host. *Oral Surgery, Oral Medicine, and Oral Pathology* **103** (6), 1-14
- Sobel JD, Myers PG, Kaye D, Levison ME** (1981) Adherence of *Candida albicans* to human vaginal and buccal epithelial cells. *Journal of Infectious Diseases* **143**, 78-82
- Sobel JD, Obedeanu N** (1983) Effects of sub-inhibitory concentrations of ketoconazole on *in vitro* adherence of *Candida albicans* to vaginal epithelial cells. *European Journal of Clinical Microbiology* **2**, 445-452
- Soll DR** (1992) High-frequency switching in *Candida albicans*. *Clinical Microbiology Reviews* **5**, 183-203
- Taweekhaisupapong S, Leela-aphiradee N, Laoprom P, Khamenkhon P** (2000a) Effects of Koi *Streblus asper* on root canal bacteria. *Khon Kaen University Dental Journal* **3**, 41-47
- Taweekhaisupapong S, Singhara S, Choopan T** (2002a) Antimicrobial effect of *Streblus asper* leaf extract on selected anaerobic bacteria. *The Journal of the Dental Association of Thailand* **52**, 227-234
- Taweekhaisupapong S, Wongkham S, Rattanathongkom A, Singhara S, Choopan T, Suparee S** (2002b) Effect of mouthrinse containing *Streblus asper* leaf extract on gingivitis and plaque formation. *The Journal of the Dental Association of Thailand* **52**, 383-391
- Taweekhaisupapong S, Choopan T, Singhara S, Chatrchaiwiwatana S, Wongkham S** (2005) *In vitro* inhibitory effect of *Streblus asper* leaf-extract on adhesion of *Candida albicans* to human buccal epithelial cells. *Journal of Ethnopharmacology* **96**, 221-226
- Van Wyk B-E, Van Oudtshoorn B, Gericke N** (2002) *Medicinal Plants of South Africa*, Briza Publications, Pretoria, pp 108-109
- Wagner H, Blatt S** (1996) *Plant Drug Analysis: A Thin Layer Chromatography Atlas*, Springer, Berlin, 384 pp
- Williams DW, Potts AJ, Wilson MJ, Matthews JB, Lewis MA** (1997) Characterization of the inflammatory cell infiltrate in chronic hyperplastic candidosis of the oral mucosa. *Journal of Oral Pathology and Medicine* **26**, 83-89